Ubrogepant Dosage and Clinical Considerations for Migraine Treatment

Place in Therapy

Ubrogepant is considered a third-line medication for acute migraine treatment, according to the American Academy of Neurology, and should be considered for patients who do not tolerate or have inadequate response to combination therapy of a triptan and an NSAID or acetaminophen, with a moderate strength of evidence 1
The American College of Physicians recommends considering ubrogepant for patients who do not respond to first-line treatments, with a high strength of evidence 2

The American Headache Society suggests beginning treatment as soon as possible after migraine onset for optimal efficacy, with a strong recommendation 2
For patients with significant nausea or vomiting during migraine attacks, the European Neurological Society recommends considering adding an antiemetic, with a moderate strength of evidence 1
The American Academy of Neurology advises monitoring for medication overuse headache, which can occur with frequent use of acute migraine treatments, with a high strength of evidence 2

Ubrogepant is not indicated for the preventive treatment of migraine, according to the American College of Neurology, and is more expensive than first-line treatments such as NSAIDs or triptans, with a low strength of evidence 2